PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Clinical trials for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE explained in plain language.
Never miss a new study
Get alerted when new PULMONARY DISEASE, CHRONIC OBSTRUCTIVE trials appear
Sign up with your email to follow new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can pharmacists ease the burden of COPD care? major VA trial investigates
Disease control Recruiting nowThis study tests whether clinical pharmacists can manage COPD patients as effectively as lung specialists. Pharmacists and specialists will review patient records and send treatment recommendations to primary care doctors, who then approve or adjust them. The goal is to see if th…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: NA • Sponsor: Seattle Institute for Biomedical and Clinical Research • Aim: Disease control
Last updated Apr 01, 2026 23:41 UTC
-
Common aspirin could ease breathing for millions with COPD
Disease control Recruiting nowThis study is testing which daily dose of aspirin (81mg, 162mg, or 325mg) best reduces blood cell inflammation linked to worse COPD symptoms. Researchers will enroll 48 adults with COPD who are former smokers. The goal is to find the most effective dose to inform a larger future …
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: PHASE3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New inhaler aims to help lungs breathe easier in COPD trial
Disease control Recruiting nowThis study is testing a new inhaled powder called TQC3721 for people with moderate to severe chronic obstructive pulmonary disease (COPD). About 195 participants will use the inhaler or a placebo for 4 weeks to see if it improves their lung function and quality of life. The main …
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New shot aims to tame COPD Flare-Ups
Disease control Recruiting nowThis large study is testing if adding a new injectable medicine called depemokimab to standard inhaler therapy can help control Chronic Obstructive Pulmonary Disease (COPD). It aims to see if the medicine reduces the number of serious breathing flare-ups that require steroids, an…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New shot aims to tame dangerous COPD Flare-Ups
Disease control Recruiting nowThis study is testing whether a new injectable medicine called depemokimab can help adults with a specific type of COPD (chronic obstructive pulmonary disease) who continue to have flare-ups despite using standard inhalers. The main goal is to see if the medicine reduces the numb…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Tracking a year of COPD care: does a triple therapy deliver?
Disease control Recruiting nowThis study looks back at data from real-world patients with moderate to severe COPD who started a triple-combination inhaler (BGF). It aims to see how their symptoms, quality of life, and number of flare-ups change over 12 months compared to before starting the treatment. The goa…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC